0000950170-23-000875.txt : 20230118 0000950170-23-000875.hdr.sgml : 20230118 20230118163636 ACCESSION NUMBER: 0000950170-23-000875 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230118 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230118 DATE AS OF CHANGE: 20230118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SQZ Biotechnologies Co CENTRAL INDEX KEY: 0001604477 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462431115 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39662 FILM NUMBER: 23534852 BUSINESS ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., STE. 210 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-898-8824 MAIL ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., STE. 210 CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 sqz-20230118.htm 8-K 8-K
0001604477false00016044772023-01-182023-01-18

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 18, 2023

 

 

SQZ BIOTECHNOLOGIES COMPANY

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39662

46-2431115

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

200 Arsenal Yards Blvd

Suite 210

 

Watertown, Massachusetts

 

02472

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617 758-8672

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

SQZ

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 18, 2023, SQZ Biotechnologies Company (the “Company”) received notice (the “NYSE Notification”) from the New York Stock Exchange (“NYSE”) indicating that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period. The NYSE Notification does not result in the immediate delisting of the Company’s common stock from the NYSE.

 

The Company plans to notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the NYSE continued listing standards. Under NYSE rules, the Company has a period of six months from receipt of the NYSE Notification to cure the stock price deficiency and regain compliance with the NYSE’s continued listing standards. The Company can regain compliance at any time within such cure period if, on the last trading day of any calendar month during the cure period, the Company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The Company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to stockholder approval at the Company’s next annual meeting of stockholders, if necessary to cure the stock price deficiency.

 

The Company’s common stock will continue to be listed and trade on the NYSE during this cure period, subject to the Company’s compliance with other NYSE continued listing standards.

Item 7.01 Regulation FD Disclosure.

As required by Section 802.01C, on January 18, 2023, the Company issued a press release announcing that it had received the NYSE Notification. A copy of the press release is furnished as Exhibit 99.1 attached hereto and is incorporated herein by reference.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to the NYSE’s continued listing standards, the Company’s ability to return to and maintain compliance with these standards and the Company’s plans to cure the stock price deficiency. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to the Company’s ability to regain compliance with the NYSE’s continued listing standards within the applicable cure period; the Company’s ability to continue to comply with the applicable NYSE continued listing standards; the Company’s limited operating history; the Company’s significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; the Company’s ability to continue as a going concern; the Company’s ability to successfully execute or achieve the benefits of its strategic prioritization and other cost saving measures; the development of the Company’s initial product candidates, upon which its business is highly dependent; the impact of the COVID-19 pandemic on the Company’s operations and clinical activities; the Company’s need for additional funding and its cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; the Company’s ability to maintain its relationships with its third party vendors; and protection of the Company’s proprietary technology, intellectual property portfolio and the confidentiality of its trade secrets. These and other important factors discussed under the caption "Risk Factors" in the Company’s Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of the date of this Current Report on Form 8-K and the Company undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


 



 

 

Exhibit No.

 

Description

99.1

 

Press release issued by SQZ Biotechnologies Company on January 18, 2023.



104

 

Cover Page Interactive Data File (embedded with the Inline XBRL document).

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SQZ BIOTECHNOLOGIES COMPANY

 

 

 

 

Date:

January 18, 2023

By:

/s/ Lawrence Knopf

 

 

 

General Counsel

 

 EX-99.1 2 sqz-ex99_1.htm EX-99.1 EX-99.1

Empower Cells to Change Livesimg61662729_0.jpg®

EXHIBIT 99.1

 

SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards
From the New York Stock Exchange

 

WATERTOWN, Mass., January 18, 2023 – SQZ Biotechnologies (NYSE: SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s common stock from the NYSE.

 

The Company plans to notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the NYSE’s continued listing standards. Under NYSE rules, the Company has a period of six months from receipt of the NYSE notice to cure the stock price deficiency and regain compliance with the NYSE’s continued listing standards. The Company can regain compliance at any time within such cure period if, on the last trading day of any calendar month during the cure period, the Company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The Company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to stockholder approval at the Company’s next annual meeting of stockholders, if necessary to cure the stock price deficiency. The Company’s common stock will continue to be listed and trade on the NYSE during this cure period, subject to SQZ Biotechnologies’ compliance with other NYSE continued listing standards.

 

About SQZ Biotechnologies

SQZ Biotechnologies is a clinical-stage biotechnology Company focused on unlocking the full potential of cell therapies. The Company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could change the way people think about cell therapies. For more information, please visit www.sqzbiotech.com.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements relating to the NYSE’s continued listing standards, the Company’s ability to return to and maintain compliance with these standards and the Company’s plans to cure the stock price deficiency. These forward-looking statements are based on management's current expectations. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, risks and uncertainties related to our ability to regain compliance with the NYSE’s continued listing standards within the applicable cure period; our ability to continue to comply with the applicable NYSE continued listing standards; our limited operating history; our significant losses incurred since inception and expectation to incur significant additional losses for the foreseeable future; our ability to continue as a going concern; our ability to successfully execute or achieve

 

 

Empower Cells to Change Livesimg61662729_0.jpg®

the benefits of our strategic prioritization and other cost saving measures; the development of our initial product candidates, upon which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional funding and our cash runway; the lengthy, expensive, and uncertain process of clinical drug development, including uncertain outcomes of clinical trials and potential delays in regulatory approval; our ability to maintain our relationships with our third party vendors; and protection of our proprietary technology, intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K, and other filings with the U.S. Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent management's estimates as of the date of this press release and SQZ undertakes no duty to update these forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, unless required by law.

 

 

Empower Cells to Change Livesimg61662729_0.jpg®

Investor Relations and Media Contact

Mike Kaiser

857-760-0398

michael.kaiser@sqzbiotech.com

 

 

 GRAPHIC 3 img61662729_0.jpg GRAPHIC begin 644 img61662729_0.jpg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end EX-101.SCH 4 sqz-20230118.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 sqz-20230118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 6 sqz-20230118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Jan. 18, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 18, 2023
Entity Registrant Name SQZ BIOTECHNOLOGIES COMPANY
Entity Central Index Key 0001604477
Entity Emerging Growth Company true
Securities Act File Number 001-39662
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-2431115
Entity Address, Address Line One 200 Arsenal Yards Blvd
Entity Address, Address Line Two Suite 210
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 617
Local Phone Number 758-8672
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SQZ
Security Exchange Name NYSE
XML 8 sqz-20230118_htm.xml IDEA: XBRL DOCUMENT 0001604477 2023-01-18 2023-01-18 0001604477 false 8-K 2023-01-18 SQZ BIOTECHNOLOGIES COMPANY DE 001-39662 46-2431115 200 Arsenal Yards Blvd Suite 210 Watertown MA 02472 617 758-8672 N/A false false false false Common Stock, $0.001 par value per share SQZ NYSE true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P M6BP^0"X99K>]9!:G7&BN"^)]NK+NY *W3"W\RQ+50/>I"MJ M(-.)_#1EZA$VY8<1(86>Y4)88TS<;_3\1C0>09:'[L#TA(XA+@W#"CTN*+N@U6/ M@24DM0H#E>QV3N7TR@ZN6>1>9!CG*(.XLH/P4:V%&@/8-SF0!)?DJG547>EY MIM[IFBG#S^0W1U MW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@ M;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ DH0R5F60>9(9 M 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL M6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4 M'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY M'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?K MT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y; M@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$" M% ,4 " "2A#)6!T%-8H$ "Q $ @ $ 9&]C M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( )*$,E;?LXK$[@ "L" 1 M " :\ !D;V-0&UL4$L! A0#% @ DH0R5DTV'#:\! C!( !@ M ("!#0@ 'AL+W=O7!E&UL4$L%!@ ) D /@( ' & 4 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports sqz-20230118.htm sqz-20230118.xsd sqz-20230118_lab.xml sqz-20230118_pre.xml sqz-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sqz-20230118.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "sqz-20230118.htm" ] }, "labelLink": { "local": [ "sqz-20230118_lab.xml" ] }, "presentationLink": { "local": [ "sqz-20230118_pre.xml" ] }, "schema": { "local": [ "sqz-20230118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sqz", "nsuri": "http://sqzbiotech.com/20230118", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "sqz-20230118.htm", "contextRef": "C_80d96aa6-c41d-4afd-aa52-214f0ef59775", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "sqz-20230118.htm", "contextRef": "C_80d96aa6-c41d-4afd-aa52-214f0ef59775", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20230118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-000875-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-000875-xbrl.zip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end